Search Results - kras

4 Results

Sort By:

Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)

Abstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes tumor infiltrating lymphocytes (TILs) or genetically engineered T cells to attack tumor cells through recognition of tumor-specific antigens. A major hurdle in the development of ACT is the identification and isolation of T cells that recognize antigens...

Published: 5/8/2024 | Inventor(s):

Keywords(s): act, adoptive cell therapy, Antigen Presenting Cells, APC, cell lines, HLA, Human Leukocyte Antigen, Immunotherapy, KRAS, Levin, p53, Rosenberg, T Cell Receptor, TCR, TIL, Tumor Infiltrating Lymphocytes, Tumor-Specific Antigen

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Research Materials, TherapeuticArea > Infectious Disease

Improved Production of Prenylated Protein in Insect Cells

Abstract: KRAS and other Ras-family enzymes are an important component of over 30% of human cancers, however, no effective therapeutics targeting Ras or Ras-driven cancers are currently available. The production of Ras proteins in vitro is required for the identification and characterization of Ras targeting drugs. An important step in producing the...

Published: 5/22/2024 | Inventor(s): Dominic Esposito, Carissa Grose, William Gillette

Keywords(s): CANCER, KRAS, RAS, RESEARCH MATERIAL

Category(s): Application > Research Materials, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations

Abstract: Several malignancies associated with a poor prognosis such as lung, pancreatic and colorectal cancers frequently harbor constitutively active KRAS mutants, which play a pivotal role in oncogenesis. Currently, there are no potentially curative treatments against most mutant KRAS harboring cancers once they become metastatic and unresectable. ...

Published: 4/8/2024 | Inventor(s): Qiong Wang, James Yang, Zhiya Yu

Keywords(s): Colorectal, Immunotherapy, KRAS, LUNG, oncogenesis, PANCREAS, PROSTATE, T cell, TCR

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Two-Target Treatment that Inhibits Cancer Growth

Targets Thymidylate Synthase and Oncogenic Ras Signaling in Ras Mutant TumorsThis combination strategy contains inhibitors and pharmaceutically acceptable excipients for the treatment of various forms of cancer, such as breast cancer, prostate cancer, brain cancer, or pancreatic cancer. Cancer is the second leading cause of death in the United States....

Published: 6/27/2021 | Inventor(s): Maria Zajac-Kaye, Rony Francois

Keywords(s): Cancer, Drug combination, KRAS, RAS effectors, Thymidylate synthase

Category(s): Technology Classifications > Human Health Care > Therapeutics